Super-Resolution Ultrasound of the Brain in 3D

Launched by ASSISTANCE PUBLIQUE - HÔPITAUX DE PARIS · Nov 9, 2023

Keywords

ClinConnect Summary

This clinical trial, titled "Super-Resolution Ultrasound of the Brain in 3D," is investigating a new way to see blood vessels in the brain after a stroke. The researchers want to find out if they can use a special type of ultrasound imaging to visualize the middle cerebral artery and its smaller branches. This could help doctors determine if there is a blockage in these vessels, which is important for diagnosing an ischemic stroke—a type of stroke caused by a blockage in blood flow.

To participate in this study, individuals must be at least 18 years old and have recently experienced an ischemic stroke that can be seen on an MRI scan. The trial is open to all genders and is currently recruiting participants who are within 7 days of their stroke. If you join the study, you will undergo a transtemporal ultrasound, a safe and painless procedure, to gather important information about your condition. The results from this ultrasound will be compared with standard imaging tests like CT and MRI to see how well this new method works. Before joining, participants will need to provide informed consent and meet specific health criteria to ensure their safety.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Patient aged 18 and over
• • Hospitalized patient with ischemic stroke in the deep territory of the middle cerebral artery
• • Patient with lesion observable on MRI
• • Patient included between 24 hours and 7 days after the ischemic stroke
• • Patient with a temporal window which allows soundproofing of the polygon of Willis and the middle cerebral artery
• • Patient having signed free, informed and written consent
• • Patient affiliated to a social security system (excluding AME)
• Exclusion Criteria:
• • Contralateral middle cerebral artery territory stroke or contralateral middle cerebral artery occlusion
• • Patient with contraindication to Doppler ultrasound with contrast (right-left shunt, severe pulmonary arterial hypertension)
• • Patient with hypersensitivity to the active princip of Sonovue (sulfur hexafluoride) or these excipients
• • Patient with uncontrolled systemic hypertension
• • Patient with respiratory distress syndrome
• • Patient under guardianship or curatorship
• • Pregnant or breastfeeding patient (positive blood pregnancy test during hospitalization)
• • Patient with damaged skin at the temporal level
• • Patient having presented in the 7 days preceding inclusion an acute coronary syndrome or suffering from unstable ischemic heart disease